Table 2.

Characteristics of the treatments administered to the patients

Adjuvant chemotherapy (cycles), n = 231	n	%
With docetaxel	157	68
TAC × 6	46	20
ET × 4 → X × 4	39	17
EC × 4 → T × 4	39	17
AT × 4 → CMF × 4	21	9
A × 3 → T × 3 → CMF × 3	12	5
With paclitaxel	74	32
FAC × 4 → T × 8	48	21
AT × 4 → CMF × 3	13	5
FEC × 4 → T × 8	11	5
AC × 4 → T × 8 or T × 12	2	1

Chemotherapy administration, n = 231	n	%
Delayed cycles
<2 cycles	216	94
≥2 cycles	15	6
Delayed days
<15 days	226	98
≥15 days	5	2
Relative dose intensity
≥85 %	226	98
<85 %	5	2

Prophylaxis with G-CSF, n = 231	n	%
Yes	84	36
Primary prophylaxis	55	24
Secondary prophylaxis	29	12
No	147	64
G-CSF given later to treat neutropenia	8	3

A doxorubicin, C cyclophosphamide, E epirubicin, F 5-fluorouracil, G-CSF granulocyte colony-stimulating factor, M methotrexate, T taxane (docetaxel or paclitaxel), X capecitabine